Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingRichard A Graham, Bert L Lum, Sravanthi Cheeti, et al.
British Journal of Clinical Pharmacology|March 31, 2012
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsRichard A Graham, Cornelis E C A Hop, Marie T Borin, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesChris J Wynne, Rod B Ellis-Pegler, Devonie S Waaka, et al.
Annals of the New York Academy of Sciences|June 12, 2003
Marrow stem cell potential within a continuumP Quesenberry, G Colvin, J F Lambert, et al.
Cancer Research|July 1, 1986
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsyF M Torti, M M Bristow, B L Lum, et al.
Journal of Molecular Endocrinology|February 10, 2004
Expressions of hepatic genes, especially IGF-binding protein-1, correlating with serum corticosterone in microarray analysisR Y S Cheng, L A Birely, N L Lum, et al.
Journal of Medicinal Chemistry|March 29, 2011
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449)Anthony M Giannetti, Harvey Wong, Gerrit J P Dijkgraaf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 24, 2011
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometryRichard A Graham, Bert L Lum, Glenn Morrison, et al.
Pageof 17